투자판단관련주요경영사항(임상시험계획승인신청) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)[코]
Received: 3/19/2026 · Reporter: 삼천당제약
A summary for this filing type is not yet available. Please refer to the original DART filing.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 32 filings
- Same category
- 25 filings
- Previous same-category filing
- 6/10/2026
- Corrections / withdrawals
- 3 filings
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).